Angiotensin-Converting Enzyme Inhibition Intervention in Elderly Persons: Effects on Body Composition and Physical Performance
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
The disablement process is often accompanied by sarcopenia or muscle loss, which is associated with virtually all identified disability risk factors. Clinically, the association between body composition and physical performance has been documented by several studies. However, loss of strength is greater than loss of muscle mass with age implying that the quality of remaining muscle may be reduced. Although there are limited data explaining potential physiological mechanisms that contribute to muscle quality, sarcopenia is frequently associated with fat accumulation, and the percentage of body fat increases with age even if weight does not. However, the relationship between fat and muscle function may not be linear, suggesting that there may be an optimal ratio of lean to fat mass for physical function. There are no definitive pharmacological interventions proven to prevent decline in physical function either by modulating body composition or by other means. One exception may be angiotensin-converting enzyme inhibitors (ACEIs). ACE is an important component of the renin-angiotensin system, the central hormonal regulator of blood pressure. Recent evidence suggests that ACEIs may improve physical function by means of direct effects on body composition in older persons, rather than through its blood-pressure-lowering effects. Clinical and genetic studies in humans and experimental evidence in animals suggest that modulation of the renin-angiotensin system is associated with metabolic and biochemical changes in skeletal muscle and fat, changes that are associated with declining physical function. ACEIs may modulate this process through a variety of molecular mechanisms including their influence on oxidative stress and on metabolic and inflammation pathways. This review describes potential biological mechanisms of ACE inhibition and its contribution to declining physical performance and changing body composition. Promising pharmacoepidemiological studies and experimental evidence in animals suggest that there are appropriate models in which to study this effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pfeffer, M. A., McMurray, J. J. V., Velazquez, E. J., Rouleau, J.-L., Køber, L., Maggioni, A. P., Solomon, S. D., Swedberg, K., Van de Werf, F., White, H., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032292 · Cited by 2,471 · cited 1×
“Interestingly, valsartan, in addition to ACEI treatment, significantly reduced the combined end point of mortality and morbidity (111,112).”
BackgroundAssociations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly
Harris, T. B., Ferrucci, L., Tracy, R. P., Corti, M. C., Wacholder, S., Ettinger, W. H., Heimovitz, H., Cohen, H. J., & Wallace, R. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00066-2 · Cited by 1,488 · cited 1×
“Stronger evidence from a prospective study by Harris and colleagues (84) of a subset of this population has demonstrated an association between elevated levels of IL-6 and C-reactive protein and mortality in a group of nondisabled persons from the Established Population for the Epidemiologic Study of the Elderly (EPES…”
BackgroundGene expression profile of aging and its retardation by caloric restriction
Lee, C.-K., Klopp, R. G., Weindruch, R., & Prolla, T. A. (1999) · Science · doi:10.1126/science.285.5432.1390 · Cited by 1,473 · cited 1×
“that are observed in ad libitum-fed animals (8,9).”
BackgroundKelley, D. E., Goodpaster, B., Wing, R. R., & Simoneau, J.-A. (1999) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1999.277.6.e1130 · Cited by 1,096
Messier, S. P., Loeser, R. F., Miller, G. D., Morgan, T. M., Rejeski, W. J., Sevick, M. A., Ettinger, W. H., Pahor, M., & Williamson, J. D. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20256 · Cited by 1,065
Self-citationSerum IL‐6 Level and the Development of Disability in Older Persons
Ferrucci, L., Harris, T. B., Guralnik, J. M., Tracy, R. P., Corti, M., Cohen, H. J., Penninx, B., Pahor, M., Wallace, R., & Havlik, R. J. (1999) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1999.tb01583.x · Cited by 809
Self-citationGoodpaster, B. H., Krishnaswami, S., Resnick, H., Kelley, D. E., Haggerty, C., Harris, T. B., Schwartz, A. V., Kritchevsky, S., & Newman, A. B. (2003) · Diabetes Care · doi:10.2337/diacare.26.2.372 · Cited by 619
Self-citationBinder, E. F., Schechtman, K. B., Ehsani, A. A., Steger‐May, K., Brown, M., Sinacore, D. R., Yarasheski, K. E., & Holloszy, J. O. (2002) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2002.50601.x · Cited by 549
Newman, A. B., Haggerty, C. L., Goodpaster, B., Harris, T., Kritchevsky, S., Nevitt, M., Miles, T. P., Visser, M., & The Health, A. (2003) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2003.51105.x · Cited by 505 · cited 1×
“muscle quality compared to those in the midrange (1),”
BackgroundSelf-citationThe Association of Plasma IL-6 Levels With Functional Disability in Community-Dwelling Elderly
Cohen, H. J., Pieper, C. F., Harris, T., Rao, K. M. K., & Currie, M. S. (1997) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/52a.4.m201 · Cited by 476
Cited by
Fielding, R. A., Vellas, B., Evans, W. J., Bhasin, S., Morley, J. E., Newman, A. B., Abellan van Kan, G., Andrieu, S., Bauer, J., Breuille, D., et al. (2011) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2011.01.003 · Cited by 3,256
“This may explain the association of angiotensin converting enzyme inhibitors with increase muscle mass (55).”
BackgroundSelf-citationSarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives
Rolland, Y., Czerwinski, S., van Kan, G. A., Morley, J. E., Cesari, M., Onder, G., Woo, J., Baumgartner, R., Pillard, F., Boirie, Y., et al. (2008) · The Journal of nutrition, health and aging · doi:10.1007/bf02982704 · Cited by 1,071
“Growing evidence suggests that ACE inhibitors may prevent sarcopenia ((313, 314) and see (258) for review).”
BackgroundSelf-citationMitochondrial dysfunction and sarcopenia of aging: from signaling pathways to clinical trials
Marzetti, E., Calvani, R., Cesari, M., Buford, T. W., Lorenzi, M., Behnke, B. J., & Leeuwenburgh, C. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.06.024 · Cited by 627
Sarcopenia: Diagnosis and treatment
Morley, J. E. (2008) · The Journal of nutrition, health and aging · doi:10.1007/bf02982705 · Cited by 402
Arterial stiffness is associated with low thigh muscle mass in middle-aged to elderly men
Ochi, M., Kohara, K., Tabara, Y., Kido, T., Uetani, E., Ochi, N., Igase, M., & Miki, T. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.05.026 · Cited by 252
Metadata
- Authors
- Carter, C. S., Onder, G., Kritchevsky, S. B., & Pahor, M.
- Venue
- The Journals of Gerontology Series A: Biological Sciences and Medical Sciences
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-11-01
- Volume
- 60
- Issue
- 11
- Pages
- 1437-1446
- ISSN
- 1079-5006 (ISSN-L)
- 1758-535X
- OpenAlex
- W2114940358
- Cited by
- 80
- References
- 23
- FWCI
- 2.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Angiotensin-Converting Enzyme Inhibition Intervention in Elderly Persons: Effects on Body Composition and Physical Performance. https://app.cochat.ai/papers/10.1093/gerona/60.11.1437
- The paper
- Carter, C. S., Onder, G., Kritchevsky, S. B., & Pahor, M. (2005). Angiotensin-Converting Enzyme Inhibition Intervention in Elderly Persons: Effects on Body Composition and Physical Performance. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. https://doi.org/10.1093/gerona/60.11.1437
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.